Barclays
TTNP

Barclays’s Titan Pharmaceuticals TTNP Stock Holding History

Barclays’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,503
Closed -$48K – 5273
2022
Q1 		$48K Buy
+2,503
New +$52K ﹤0.01% 4134
2019
Q4 		– Hold
0
– – – 6825
2019
Q3 		– Hold
0
– – – 7131
2019
Q2 		– Hold
0
– – – 7283
2019
Q1 		– Hold
0
– – – 7330
2018
Q4 		– Hold
0
– – – 7336
2018
Q3 		– Hold
0
– – – 7399
2018
Q2 		– Hold
0
– – – 7290
2018
Q1 		– Hold
0
– – – 7337
2017
Q4 		– Hold
0
– – – 7118
2017
Q3 		– Sell
-7
Closed -$47K – 7051
2017
Q2 		$47K Buy
7
+5
+250% +$46.5K ﹤0.01% 5396
2017
Q1 		$18K Buy
+2
New +$28.1K ﹤0.01% 5855
2016
Q4 		– Hold
0
– – – 6498
2016
Q3 		– Hold
0
– – – 6450

Other funds holding TTNP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's TTNP Position: Q2 2022 in Review

Barclays sold out of Titan Pharmaceuticals (TTNP) in Q2 2022, closing a stake of 2,503 shares — an estimated $48K sold.

Barclays first reported a position in TTNP in Q1 2017 and held it in 3 quarters. The position peaked at $48K in Q1 2022. 19 funds tracked by Wall St. Rank hold TTNP as of Q2 2022.

  • Barclays reported no remaining Titan Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 2,503 Titan Pharmaceuticals shares in Q2 2022, an estimated $48K.
  • Barclays first reported a position in Titan Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • Barclays's Titan Pharmaceuticals position peaked at $48K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.